ClinicalTrials.gg
CompletedNCT04051736Updated Sep 9, 2020

Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

A Phase 4 interventional study of Inactivated Polio Vaccine in Vaccination, sponsored by China National Biotec Group Company Limited. Completed at 1 site in China. Open to participants aged 60 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2018, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
60 Days to 89 Days
Sex
All
01

Study summary

This study replaced the 2nd and 3rd dose of Salk-IPV (produced by Sanofi) with Sabin-IPV (produced by CNBG) and then reviewed the safety and immunogenicity of the vaccination, aiming to acquire scientific evidence for the feasibility of immunization involving different viral strains replacement.

Read the detailed description

It is required by China Food and Drug Administration (CFDA) that considering in the real situation IPV receivers may be immuned by different viral strains of this vaccine, a phase 4 clinical trial aiming to demonstrate the safety and immunogenicity of the immunization schedule should be carried out. To be specific, the subjects were divided into 2 groups.

Group 1 received Salk-IPV+Sabin-IPV+Sabin-IPV respectively at the age of 2,3,4 months old.

Group 2 received Salk-IPV+Salk-IPV+Salk-IPV respectively at the age of 2,3,4 months old.

Blood sample was collected before vaccination and 30 days after the third dose of vaccination. Neutralization antibody against type I, Type II and Type III poliomyelitis virus were detected to evaluate the seroprotection rates and antibody geometric mean concentrations. The safety of both immunization schedule will also been monitored.

02

Conditions studied

  • Vaccination
03

In context

Lead sponsor

China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.

First submitted after China National Biotec Group Company Limited became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects aged from 60 days to 89 days old at the date of recruitment;
  • with signed by parent(s) or guardians;
  • parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;
  • subjects did not receive any vaccines within 14 days;
  • axillary temperature ≤37.0℃

Exclusion criteria

Exclusion Criteria:

  • allergic to any ingredient of vaccine or with allergy history to any vaccine;
  • acute febrile disease or infectious disease;
  • serious chronic diseases;
  • any other factor that makes the investigator determines the subject is unsuitable for this study;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    group 1

    180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV

    Biological: Inactivated Polio Vaccine

  • Active comparator
    group 2

    180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV

    Biological: Inactivated Polio Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Seroconversion rate

    determine the seroconversion rate of both groups

    Time frame: 4 months

Secondary outcomes

  1. Neutralizing antibody titers

    Measure neutralizing antibody titers against poliovirus type I, II and III

    Time frame: 4 months

Other outcomes

  1. number of participants who experience adverse events

    analyse the number and rate of vaccine participants who have adverse events following immunization

    Time frame: 6 months

07

Study locations

1 site
  • Beijing Center for Disease Control and Prevention
    Beijing, Beijing 100013, China
08

References and documents

Publications

  • Chen H, Gao Z, Bai S, Liu X, Han S, Xiao Y, Liu F, Yu Y, Sun H, Yang X. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement. Vaccine. 2021 Apr 22;39(17):2467-2474. doi: 10.1016/j.vaccine.2021.02.073. Epub 2021 Mar 31. PubMed 33810904 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Dec 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 9, 2019
StartActual
Mar 1, 2018
Primary completionActual
Dec 28, 2018
CompletionActual
Aug 31, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04051736
Collaborators
Beijing Institute of Biological Products Co Ltd., Beijing Center for Disease Control and Prevention, Peking University
Responsible party
Sponsor
First posted
Aug 9, 2019
Start date
Mar 1, 2018
Primary completion
Dec 28, 2018
Completion
Aug 31, 2020
Last update
Sep 9, 2020

Study contacts

Jiang WU
study director · Beijing Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poliovirus Vaccine, Inactivated

Start the discussion